In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


$65m Series D supports Pearl's twice-daily COPD combo but more funds needed

This article was originally published in Scrip

Executive Summary

Pearl Therapeutics has raised $65 million in a Series D venture financing round to kick-start its Phase III development plan for the inhaled chronic obstructive pulmonary disease (COPD) drug candidate PT003, but it will need more cash from another private funding deal, a partnership or an initial public offering to complete two planned pivotal trials.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts